Black Titan Corp (NASDAQ:BTTC) Sees Large Growth in Short Interest

Black Titan Corp (NASDAQ:BTTC) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 77,733 shares, an increase of 3,138.9% from the June 15th total of 2,400 shares. Based on an average daily volume of 905,542 shares, the short-interest ratio is presently 0.1 days. Currently, 1.6% of the company’s stock are short sold.

Black Titan Trading Down 5.8%

Shares of NASDAQ BTTC traded down $0.05 during trading hours on Friday, hitting $0.76. The company had a trading volume of 15,047 shares, compared to its average volume of 481,150. Black Titan has a 1-year low of $0.68 and a 1-year high of $39.00. The company has a current ratio of 4.62, a quick ratio of 4.62 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average price is $0.97.

Black Titan (NASDAQ:BTTC) last posted its quarterly earnings results on Friday, June 12th. The company reported ($0.22) earnings per share (EPS) for the quarter. The business had revenue of $0.59 million for the quarter.

Institutional Trading of Black Titan

Several institutional investors and hedge funds have recently bought and sold shares of BTTC. Renaissance Technologies LLC bought a new position in shares of Black Titan during the 4th quarter worth approximately $26,000. HRT Financial LP bought a new stake in Black Titan in the 4th quarter valued at $28,000. Marex Group plc acquired a new stake in Black Titan during the 4th quarter valued at $84,000. Finally, Armistice Capital LLC acquired a new stake in Black Titan during the 4th quarter valued at $840,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.